Inaktiver Wert

Andere Sprachen Caladrius Biosciences Inc Nasdaq

Aktien

US1280581042

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

09.05.	Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09.05.	Lisata Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09.05.
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08.05.
Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events	08.05.
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02.05.
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024	02.05.
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24.04.
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23.04.
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23.04.
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23.04.
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23.04.
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17.04.
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09.04.
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09.04.
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03.04.
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21.03.
Sector Update: Health Care Stocks Higher in Afternoon Trading	21.03.
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21.03.
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21.03.
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Caladrius Biosciences Inc Nasdaq

Aktien

US1280581042

Andere Sprachen

Filter